Stocks and Investing
Stocks and Investing
Wed, May 24, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, May 23, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Andrew Fein Maintained (BPMC) at Strong Buy with Increased Target to $85 on, May 23rd, 2023
Andrew Fein of HC Wainwright & Co., Maintained "Blueprint Medicines Corporation" (BPMC) at Strong Buy with Increased Target from $75 to $85 on, May 23rd, 2023.
Andrew has made no other calls on BPMC in the last 4 months.
There are 4 other peers that have a rating on BPMC. Out of the 4 peers that are also analyzing BPMC, 3 agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Michael Ulz of "Morgan Stanley" Maintained at Hold with Increased Target to $55 on, Friday, May 5th, 2023
- Benjamin Chaiken of "JMP Securities" Reiterated at Hold and Held Target at $114 on, Tuesday, February 28th, 2023
- Andrew Berens of "SVB Leerink" Maintained at Hold with Decreased Target to $38 on, Friday, February 24th, 2023
This is the rating of the analyst that currently disagrees with Andrew
- Dane Leone of "Raymond James" Maintained at Strong Buy with Decreased Target to $85 on, Friday, February 17th, 2023
Contributing Sources